{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:38:12Z","timestamp":1777711092690,"version":"3.51.4"},"reference-count":49,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Immunopathol Pharmacol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Vaccination rollout against COVID-19 has started in developed countries in early December 2020. Mass immunization for poor or low-income countries is quite challenging before 2023. Being a lower\u2013middle-income country, Bangladesh has begun a nationwide COVID-19 vaccination drive in early February 2021. Here, we aimed to assess the opinions, experiences, and adverse events of the COVID-19 vaccination in Bangladesh.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted this online cross-sectional study from 10 February 2021, to 10 March 2021, in Bangladesh. A self-reported semi-structured survey questionnaire was used using Google forms. We recorded demographics, disease history, medication records, opinions and experiences of vaccination, and associated adverse events symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We observed leading comorbid diseases were hypertension (25.9%), diabetes (21.1%), heart diseases (9.3%), and asthma (8.7%). The most frequently reported adverse events were injection site pain (34.3%), fever (32.6%), headache (20.2%), fatigue (16.6%), and cold feeling (15.4%). The chances of having adverse events were significantly higher in males than females ( p = 0.039). However, 36.4% of respondents reported no adverse events. Adverse events usually appeared after 12\u00a0h and went way within 48\u00a0h of vaccination. Besides, 85.5% were happy with the overall vaccination management, while 88.0% of the respondents recommended the COVID-19 vaccine for others for early immunization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>According to the present findings, reported adverse events after the doses of Covishield in Bangladesh were non-serious and temporary. In Bangladesh, the early vaccination against COVID-19 was possible due to its prudent vaccine deal, previous mass vaccination experience, and vaccine diplomacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20587384211065628","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T20:33:50Z","timestamp":1639600430000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":35,"title":["The COVID-19 vaccination experience in Bangladesh: Findings from a cross-sectional study"],"prefix":"10.1177","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2820-3144","authenticated-orcid":false,"given":"Md. Rabiul","family":"Islam","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moynul","family":"Hasan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jagannath University, Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waheeda","family":"Nasreen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Ismail","family":"Tushar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, North South University, Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohiuddin Ahmed","family":"Bhuiyan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"bibr1-20587384211065628","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6922e1"},{"key":"bibr2-20587384211065628","unstructured":"WHO Coronavirus Disease (COVID-19) Dashboard. https:\/\/covid19.who.int\/(accessed September 30 2021)."},{"key":"bibr3-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1177\/10105395211021686"},{"key":"bibr4-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.324510.1002\/hpm.3245"},{"key":"bibr5-20587384211065628","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3578841"},{"key":"bibr6-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.24865"},{"key":"bibr7-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2720710.1002\/jmv.27207"},{"key":"bibr8-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhip.2021.100153"},{"key":"bibr9-20587384211065628","volume-title":"Benefits of Getting a COVID-19 Vaccine","author":"CDC"},{"key":"bibr10-20587384211065628","volume-title":"Coronavirus Disease (COVID-19): Vaccines","author":"World Health Organization","year":"2021"},{"key":"bibr11-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839"},{"key":"bibr12-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3517"},{"key":"bibr13-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250495"},{"key":"bibr14-20587384211065628","volume-title":"The UK Has Started \u2018Historic\u2019 Mass Vaccination Program against Coronavirus","author":"ABC NEWS","year":"2020"},{"key":"bibr15-20587384211065628","first-page":"1","volume":"27","author":"Lazarus JV","year":"2020","journal-title":"Nature medicine"},{"key":"bibr16-20587384211065628","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010016"},{"key":"bibr17-20587384211065628","volume-title":"My Experience of Taking the Covid-19 Vaccine","author":"The Daily Star"},{"key":"bibr18-20587384211065628","volume-title":"Statistics and Research. Coronavirus (COVID-19) Vaccinations","author":"Our World in Data","year":"2021"},{"key":"bibr19-20587384211065628","volume-title":"More than 85 Poor Countries Will Not Have Widespread Access to Coronavirus Vaccines before 2023","author":"The Economist","year":"2021"},{"key":"bibr20-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045727"},{"key":"bibr21-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1177\/00368504211026409"},{"key":"bibr22-20587384211065628","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.6.3.e34"},{"key":"bibr23-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200012150-00014"},{"key":"bibr24-20587384211065628","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7005e1"},{"key":"bibr25-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255379"},{"key":"bibr26-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.046"},{"key":"bibr27-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.325710.1002\/hpm.3257"},{"key":"bibr28-20587384211065628","volume-title":"COVID Vaccines and Safety: What the Research Says","author":"Nature","year":"2021"},{"key":"bibr29-20587384211065628","unstructured":"CDC. COVID-19 vaccine safety update. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-01\/06-COVID-Shimabukuro.pdf (accessed February 24 2021)."},{"key":"bibr30-20587384211065628","unstructured":"EMA COVID-19 Vaccine AstraZeneca. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf (accessed February 24 2021)."},{"key":"bibr31-20587384211065628","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7008e3"},{"key":"bibr32-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.07.048"},{"key":"bibr33-20587384211065628","volume-title":"Here\u2019s what Global Progress on COVID-19 Vaccination Looks like","author":"World Economic Forum","year":"2021"},{"key":"bibr34-20587384211065628","unstructured":"ASPI. China and India tussle online over vaccine diplomacy. https:\/\/www.aspistrategist.org.au\/china-and-india-tussle-online-over-vaccine-diplomacy\/ (accessed February 24 2021)."},{"key":"bibr35-20587384211065628","volume-title":"Starts Nationwide COVID Vaccination Drive","author":"Bangladesh AA","year":"2021"},{"key":"bibr36-20587384211065628","volume-title":"Covaxin and Covishield What We Know about India's Covid Vaccines","author":"BBC"},{"key":"bibr37-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/14.1.49"},{"key":"bibr38-20587384211065628","unstructured":"WHO. World Polio Day: Bangladesh continues efforts to sustain the polio-free status. https:\/\/www.who.int\/bangladesh\/news\/detail\/28-10-2019-world-polio-day-bangladesh-continues-efforts-to-sustain-the-polio-free-status (accessed February 27 2021)."},{"key":"bibr39-20587384211065628","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3933.ijam20211896"},{"issue":"3","key":"bibr40-20587384211065628","first-page":"808","volume":"30","author":"Nasir M","year":"2021","journal-title":"Mymensingh Medical Journal"},{"key":"bibr41-20587384211065628","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S326531"},{"key":"bibr42-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07376"},{"key":"bibr43-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1177\/10105395211004371"},{"key":"bibr44-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1002\/hpm.328410.1002\/hpm.3284"},{"key":"bibr45-20587384211065628","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121449"},{"key":"bibr46-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1177\/00368504211058562"},{"key":"bibr47-20587384211065628","doi-asserted-by":"publisher","DOI":"10.22092\/ARI.2021.356357.1824"},{"key":"bibr48-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemep.2021.100726"},{"key":"bibr49-20587384211065628","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2021-0251"}],"container-title":["International Journal of Immunopathology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20587384211065628","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20587384211065628","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20587384211065628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:00:07Z","timestamp":1777456807000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20587384211065628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":49,"alternative-id":["10.1177\/20587384211065628"],"URL":"https:\/\/doi.org\/10.1177\/20587384211065628","relation":{},"ISSN":["0394-6320","2058-7384"],"issn-type":[{"value":"0394-6320","type":"print"},{"value":"2058-7384","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"20587384211065628"}}